National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
In English | En español
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 11/21/2009     First Published: 7/7/2006  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?
Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Phase III Study of Adjuvant Vincristine, Dactinomycin and Doxorubicin Hydrochloride With or Without Radiotherapy or Observation Only in Younger Patients Who are Undergoing Nephrectomy for Newly Diagnosed Stage I-III Favorable Histology Wilms' Tumor

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActiveUnder 30 at diagnosisNCICOG-AREN0532
AREN0532, NCT00352534

Objectives

Primary

  1. Evaluate the overall and event-free survival of younger patients with newly diagnosed stage I favorable histology Wilms' tumor (< 2 years of age and < 550gms) treated with nephrectomy only (very low risk), or with newly diagnosed stage III favorable histology Wilms tumor with possible nephrectomy followed by vincristine, dactinomycin, doxorubicin hydrochloride, and radiotherapy (standard risk).

Secondary

  1. Determine the effects of adding doxorubicin hydrochloride to the regimen for patients with stage I or II favorable histology found to have a high-risk biological marker.
  2. Determine whether the omission of adjuvant therapy increases the incidence of contralateral kidney lesions in patients with very low-risk disease treated by nephrectomy and observation only.
  3. Determine whether the omission of adjuvant therapy increases the incidence of renal failure in patients with very low-risk disease who have metachronous relapse.
  4. Correlate study outcomes in patients with standard-risk disease with biological data from tissue collections on protocol study COG-AREN03B2.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed Wilms' tumor
    • Newly diagnosed stage I-III disease
    • Favorable histology

  • No moderate- or high-risk Wilms' predisposition syndromes

  • Must meet 1 of the following disease stratification categories:
    • Very low-risk disease
      • Stage I disease
      • Age < 2 years
      • Tumor weight < 550 g
      • Regional lymph nodes histologically negative (must have been sampled)
      • No pulmonary metastases on CT scan of chest
    • Standard-risk disease meeting 1 of the following criteria:
      • Disease does not require radiotherapy
        • LOH at chromosomes 1p and 16q for stage I or II
        • Stage I disease meeting 1 of the following criteria:
          • Age ≥ 2 years to age < 30 years
          • Tumor weight ≥ 500 g
        • Stage II disease
          • Age < 30 years
          • Any tumor weight
      • Disease requires radiotherapy
        • No LOH at chromosomes 1p and 16q*
        • Stage III disease

     [Note: *Patients with combined loss of heterozygosity at chromosomes 1p and 16q will be eligible to transfer to protocol COG-AREN0533]

  • Must be enrolled on protocol COG-AREN03B2

Prior/Concurrent Therapy:

  • No prior tumor-directed chemotherapy or radiotherapy
    • Patients transferring from AREN03B2 with LOH 1p and 16q allowed

Patient Characteristics:

  • Karnofsky performance status (PS) 50-100% for patients > 16 years old
  • Lansky PS 50-100% for patients ≤ 16 years old
  • Bilirubin (direct) ≤ 1.5 times upper limit of normal (ULN)
  • AST or ALT < 2.5 times ULN
  • Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram (standard-risk disease)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patient must use effective contraception

Expected Enrollment

600

A total of 1,300 patients will be accrued for this study.

Outcomes

Primary Outcome(s)

Overall survival at 4 years
Event-free survival at 4 years

Secondary Outcome(s)

Incidence of contralateral kidney lesions in patients with very low-risk disease
Incidence of renal failure in patients with very low-risk disease

Outline

This is a multicenter study. Patients are stratified according to clinical and biological risk factors (very low risk vs standard risk).

  • Stratum I (very low-risk disease): Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.

  • Stratum II (standard-risk, stage I or II disease with adverse biological marker): Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.

  • Stratum III (standard-risk, stage III disease): Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.

After completion of study treatment, patients are followed periodically for at least 5 years.

Trial Contact Information

Trial Lead Organizations

Children's Oncology Group

Conrad Fernandez, MD, FRCPC, Protocol chair
Ph: 902-470-7290
Elizabeth Mullen, MD, Protocol co-chair
Ph: 617-632-5291; 866-790-4500

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Clinical Trials Office - UAB Comprehensive Cancer Center
Ph: 205-934-0309
Arizona
  Phoenix
 Phoenix Children's Hospital
 Jessica Boklan
Ph: 602-546-0920
  Tucson
 Arizona Cancer Center at University of Arizona Health Sciences Center
 Clinical Trials Office - Arizona Cancer Center at University of Arizona Health Sciences Center
Ph: 520-626-9008
Arkansas
  Little Rock
 Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
 Clinical Trial Office - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Ph: 501-686-8274
California
  Downey
 Southern California Permanente Medical Group
 Robert Cooper
Ph: 323-783-5307
  Loma Linda
 Loma Linda University Cancer Institute at Loma Linda University Medical Center
 Clinical Trials Office - Loma Linda University Cancer Institute
Ph: 909-558-3375
  Long Beach
 Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
 Jerry Finklestein
Ph: 562-492-1062
  Los Angeles
 Childrens Hospital Los Angeles
 Leo Mascarenhas
Ph: 323-361-2529
  Madera
 Children's Hospital Central California
 Vonda Crouse
Ph: 559-353-5480
  Orange
 Children's Hospital of Orange County
 Violet Shen
Ph: 714-532-8636
  Sacramento
 Kaiser Permanente Medical Center - Oakland
 Vincent Kiley
Ph: 916-474-2326
 Sutter Cancer Center
 Clinical Trial Office - Sutter Cancer Center
Ph: 916-454-6595
 University of California Davis Cancer Center
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  San Diego
 Rady Children's Hospital - San Diego
 Clinical Trials Office - Rady Children's Hospital - San Diego
Ph: 858-966-5934
  San Francisco
 UCSF Helen Diller Family Comprehensive Cancer Center
 Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center
Ph: 877-827-3222
  Stanford
 Stanford Cancer Center
 Clinical Trials Office - Stanford Cancer Center
Ph: 650-498-7061
 Email: cctoffice@stanford.edu
Colorado
  Aurora
 Children's Hospital Center for Cancer and Blood Disorders
 Kelly Maloney
Ph: 720-777-6673
Connecticut
  Farmington
 Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
 Clinical Trials Office - Carole and Ray Neag Comprehensive Cancer Center
Ph: 800-579-7822
  New Haven
 Yale Cancer Center
 Clinical Trials Office - Yale Cancer Center
Ph: 203-785-5702
Delaware
  Wilmington
 Alfred I. duPont Hospital for Children
 Clinical Trials Office - Alfred I. duPont Hospital for Children
Ph: 302-651-5755
District of Columbia
  Washington
 Walter Reed Army Medical Center
 Clinical Trials Office - Walter Reed Army Medical Center
Ph: 202-782-7840
Florida
  Fort Lauderdale
 Broward General Medical Center Cancer Center
 Clinical Trials Office - Broward General Medical Center Cancer Center
Ph: 954-355-5346
  Fort Myers
 Lee Cancer Care of Lee Memorial Health System
 Clinical Trials Office - Lee Cancer Care of Lee Memorial Health System
Ph: 877-680-0008
  Gainesville
 University of Florida Shands Cancer Center
 Clinical Trials Office - University of Florida Shands Cancer Center
Ph: 888-254-7581
  Jacksonville
 Nemours Children's Clinic
 Eric Sandler
Ph: 904-697-3793
  Miami
 Baptist-South Miami Regional Cancer Program
 Doured Daghistani
Ph: 305-274-1662
 Miami Children's Hospital
 Enrique Escalon
Ph: 305-662-8360x4960
  Orlando
 Florida Hospital Cancer Institute at Florida Hospital Orlando
 Clinical Trials Office - Florida Hospital Cancer Institute
Ph: 407-303-5623
 M.D. Anderson Cancer Center at Orlando
 Vincent Giusti
Ph: 321-841-8588
 Nemours Children's Clinic - Orlando
 Paul Gordon
Ph: 407-650-7330
  Pensacola
 Sacred Heart Cancer Center at Sacred Heart Hospital
 Clinical Trials Office - Sacred Heart Cancer Center
Ph: 850-416-4611
  St. Petersburg
 All Children's Hospital
 Gregory Hale
Ph: 727-767-4176
  Tampa
 St. Joseph's Cancer Institute at St. Joseph's Hospital
 Clinical Trials Office - St. Joseph's Cancer Institute
Ph: 800-882-4123
  West Palm Beach
 Kaplan Cancer Center at St. Mary's Medical Center
 Narayana Gowda
Ph: 561-844-6363
Georgia
  Atlanta
 Winship Cancer Institute of Emory University
 Howard Katzenstein
Ph: 404-785-0853
  Augusta
 MBCCOP - Medical College of Georgia Cancer Center
 Colleen McDonough
Ph: 706-721-3626
  Savannah
 Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
 Clinical Trials Office - Curtis and Elizabeth Anderson Cancer Institute
Ph: 912-350-8568
Idaho
  Boise
 Mountain States Tumor Institute at St. Luke's Regional Medical Center
 Eugenia Chang
Ph: 208-381-2731
Illinois
  Chicago
 Children's Memorial Hospital - Chicago
 Stewart Goldman
Ph: 773-880-3270
 University of Chicago Cancer Research Center
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
  Oak Lawn
 Advocate Christ Medical Center
 Sharad Salvi
Ph: 708-684-4094
  Park Ridge
 Advocate Lutheran General Cancer Care Center
 Clinical Trials Office - Advocate Lutheran General Cancer Care Center
Ph: 847-384-3621
  Peoria
 Saint Jude Midwest Affiliate
 Stephen Smith
Ph: 309-624-4945
  Springfield
 Simmons Cooper Cancer Institute
 Clinical Trials Office - Simmons Cooper Cancer Institute
Ph: 217-545-7929
Indiana
  Indianapolis
 Indiana University Melvin and Bren Simon Cancer Center
 Clinical Trials Office - Indiana University Cancer Center
Ph: 317-274-2552
 St. Vincent Indianapolis Hospital
 Clinical Trials Office - St. Vincent Indianapolis Hospital
Ph: 317-338-2194
Iowa
  Des Moines
 Blank Children's Hospital
 Clinical Trials Office - Blank Children's Hospital
Ph: 515-241-6729
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 Cancer Information Service
Ph: 800-237-1225
Kentucky
  Lexington
 Lucille P. Markey Cancer Center at University of Kentucky
 Clinical Trials Office - Markey Cancer Center at University of Kentucky Chandler Medical Center
Ph: 859-257-3379
  Louisville
 Kosair Children's Hospital
 Clinical Trials Office - Kosair Children's Hospital
Ph: 502-629-5500
 Email: CancerResource@nortonhealthcare.org
Louisiana
  Alexandria
 Tulane Cancer Center Office of Clinical Research
 Clinical Trials Office - Tulane Cancer Center
Ph: 504-988-6121
  New Orleans
 Children's Hospital of New Orleans
 Clinical Trials Office - Children's Hospital of New Orleans
Ph: 504-894-5377
Maine
  Scarborough
 Maine Children's Cancer Program at Barbara Bush Children's Hospital
 Eric Larsen
Ph: 207-885-7565
Maryland
  Baltimore
 Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
 Joseph Wiley
Ph: 410-601-5864
 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Ph: 410-955-8804
 Email: jhcccro@jhmi.edu
Massachusetts
  Boston
 Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
 Suzanne Shusterman
Ph: 617-632-4901
 Massachusetts General Hospital
 Clinical Trials Office - Massachusetts General Hospital
Ph: 877-726-5130
  Springfield
 Baystate Regional Cancer Program at D'Amour Center for Cancer Care
 Satkiran Grewal
Ph: 413-794-5316
  Worcester
 UMASS Memorial Cancer Center - University Campus
 Christopher Keuker
Ph: 508-856-4225
Michigan
  Flint
 Hurley Medical Center
 Clinical Trials Office - Hurley Medical Center
Ph: 810-762-8057
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 David Dickens
Ph: 616-391-2086
  Grosse Pointe Woods
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Clincial Trials Office - Van Elslander Cancer Center at St. John Hospital and Medical Center
Ph: 313-343-3166
  Kalamazoo
 CCOP - Kalamazoo
 Jeffrey Lobel
Ph: 269-341-6350
  Lansing
 Breslin Cancer Center at Ingham Regional Medical Center
 Clinical Trials Office - Breslin Cancer Center at Ingham Regional Medical Center
Ph: 517-334-2765
Minnesota
  Minneapolis
 Children's Hospitals and Clinics of Minnesota - Minneapolis
 Clinical Trials Office - Children's Hospitals and Clinics of Minnesota
Ph: 612-813-5193
  Rochester
 Mayo Clinic Cancer Center
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 Gail Megason
Ph: 601-984-5220
Missouri
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Clinical Trial Office - Ellis Fischel Cancer Center
Ph: 573-882-7440
  Kansas City
 Children's Mercy Hospital
 Maxine Hetherington
Ph: 816-234-3265
  St. Louis
 Cardinal Glennon Children's Hospital
 William Ferguson
Ph: 314-577-5638
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Robert Hayashi
Ph: 314-454-4118
Nebraska
  Omaha
 Children's Hospital
 Minnie Abromowitch
Ph: 402-955-3950
 UNMC Eppley Cancer Center at the University of Nebraska Medical Center
 Clinical Trials Office - UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Ph: 800-999-5465
Nevada
  Las Vegas
 CCOP - Nevada Cancer Research Foundation
 Jonathan Bernstein
Ph: 702-732-0971
 Jonathan Bernstein
Ph: 702-732-1493
New Hampshire
  Lebanon
 Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
 Clinical Trials Office - Norris Cotton Cancer Center
Ph: 603-650-7609
 Email: cancerhelp@dartmouth.edu
New Jersey
  Hackensack
 Hackensack University Medical Center Cancer Center
 Clinical Trials Office - Hackensack University Medical Center Cancer Center
Ph: 201-996-2879
  Morristown
 Overlook Hospital
 Hazem Mahmoud
Ph: 973-971-6720
  New Brunswick
 Saint Peter's University Hospital
 Douglas Cipkala
Ph: 732-745-6674
  Paterson
 St. Joseph's Hospital and Medical Center
 Mary Bonilla
Ph: 973-754-3349
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Clinical Trials Office - University of New Mexico Cancer Center
Ph: 505-272-6972
New York
  Albany
 Albany Medical Center Hospital
 Vikramjit Kanwar
Ph: 518-262-5513x25265
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  New Hyde Park
 Schneider Children's Hospital
 Arlene Redner
Ph: 718-470-3460
  New York
 Mount Sinai Medical Center
 Birte Wistinghausen
Ph: 212-241-7022
  Syracuse
 SUNY Upstate Medical University Hospital
 Clinical Trials Office - SUNY Upstate Medical University Hospital
Ph: 315-464-5476
  Valhalla
 New York Medical College
 Fevzi Ozkaynak
Ph: 914-493-7997
North Carolina
  Asheville
 Mission Hospitals - Memorial Campus
 Clinical Trials Office - Mission Hospitals - Memorial Campus
Ph: 828-213-4150
  Chapel Hill
 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
 Clinical Trials Office - Lineberger Comprehensive Cancer Center
Ph: 877-668-0683; 919-966-4432
  Charlotte
 Blumenthal Cancer Center at Carolinas Medical Center
 Clinical Trials Office - Blumenthal Cancer Center at Carolinas Medical Center
Ph: 704-355-2884
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Durham
 Duke Comprehensive Cancer Center
 Clinical Trials Office - Duke Comprehensive Cancer Center
Ph: 888-275-3853
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Clinical Trials Office - Wake Forest University Comprehensive Cancer Center
Ph: 336-713-6771
North Dakota
  Fargo
 CCOP - MeritCare Hospital
 Nathan Kobrinsky
Ph: 701-234-7544
Ohio
  Akron
 Akron Children's Hospital
 Clinical Trials Office - Akron Children's Hospital
Ph: 330-543-3193
  Cincinnati
 Cincinnati Children's Hospital Medical Center
 Clinical Trials Office - Cincinnati Children's Hospital Medical Center
Ph: 513-636-2799
  Cleveland
 Cleveland Clinic Taussig Cancer Center
 Clinical Trials Office - Cleveland Clinic Taussig Cancer Center
Ph: 866-223-8100
 Rainbow Babies and Children's Hospital
 Yousif (Joe) Matloub
Ph: 216-844-3345
  Columbus
 Nationwide Children's Hospital
 Amanda Termuhlen
Ph: 614-722-3552
  Toledo
 Medical University of Ohio Cancer Center
 Clinical Trials Office - Medical University of Ohio Cancer Center
Ph: 419-383-6583
 Toledo Hospital
 Clinical Trials Office - Toledo Hospital
Ph: 419-824-1842
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Rene McNall-Knapp
Ph: 405-271-5311
Oregon
  Portland
 Knight Cancer Institute at Oregon Health and Science University
 Clinical Trials Office - Knight Cancer Institute at Oregon Health and Science University
Ph: 503-494-1080
 Email: trials@ohsu.edu
 Legacy Emanuel Hospital and Health Center and Children's Hospital
 Clinical Trials Office - Legacy Emanuel Hospital and Health Center and Children's Hospital
Ph: 503-413-8199
Pennsylvania
  Bethlehem
 Lehigh Valley Hospital - Muhlenberg
 Philip Monteleone
Ph: 484-884-3333
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Clinical Trials Office - Geisinger Cancer Institute
Ph: 570-271-5251
  Hershey
 Penn State Cancer Institute at Milton S. Hershey Medical Center
 Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center
Ph: 717-531-3779
 Email: CTO@hmc.psu.edu
  Philadelphia
 St. Christopher's Hospital for Children
 Clinical Trials Office - St. Christopher's Hospital for Children
Ph: 215-427-8991
Rhode Island
  Providence
 Rhode Island Hospital Comprehensive Cancer Center
 Clinical Trials Office - Rhode Island Hospital Comprehensive Cancer Center
Ph: 401-444-1488
South Carolina
  Columbia
 Palmetto Health South Carolina Cancer Center
 Clinical Trials Office - Palmetto Health South Carolina Cancer Center
Ph: 803-434-3680
  Greenville
 Greenville Hospital Cancer Center
 Clinical Trials Office - Greenville Hospital Cancer Center
Ph: 864-241-6251
Tennessee
  Memphis
 St. Jude Children's Research Hospital
 Clinical Trials Office - St. Jude Children's Research Hospital
Ph: 901-595-4644
Texas
  Austin
 Dell Children's Medical Center of Central Texas
 Clinical Trials Office - Dell Children's Medical Center of Central Texas
Ph: 512-324-8022
  Corpus Christi
 Driscoll Children's Hospital
 Clinical Trials Office - Driscoll Children's Hospital
Ph: 361-694-5311
  Dallas
 Medical City Dallas Hospital
 Carl Lenarsky
Ph: 972-566-6647x4439
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Clinical Trials Office - Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Ph: 866-460-4673; 214-648-7097
  Houston
 Baylor University Medical Center - Houston
 Patrick Thompson
Ph: 832-824-4029
 M. D. Anderson Cancer Center at University of Texas
 Clinical Trials Office - M. D. Anderson Cancer Center at the University of Texas
Ph: 713-792-3245
  Lubbock
 Covenant Children's Hospital
 Latha Prasannan
Ph: 806-725-4840
  San Antonio
 University of Texas Health Science Center at San Antonio
 Paul Thomas
Ph: 210-704-2187
  Temple
 CCOP - Scott and White Hospital
 Arlynn Mulne
Ph: 254-724-2006
Utah
  Salt Lake City
 Primary Children's Medical Center
 Phillip Barnette
Ph: 801-662-4700
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Kimberly Dunsmore
Ph: 434-924-5105
  Falls Church
 Inova Fairfax Hospital
 Clinical Trials Office - Inova Fairfax Hospital
Ph: 703-208-6650
  Norfolk
 Children's Hospital of The King's Daughters
 Eric Lowe
Ph: 757-668-7243
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939
  Roanoke
 Carilion Medical Center for Children at Roanoke Community Hospital
 Mandy Atkinson
Ph: 540-981-7376
Washington
  Spokane
 Providence Cancer Center at Sacred Heart Medical Center
 Judy Felgenhauer
Ph: 509-474-2777
  Tacoma
 Mary Bridge Children's Hospital and Health Center - Tacoma
 Ronald Louie
Ph: 253-403-3481
West Virginia
  Charleston
 West Virginia University Health Sciences Center - Charleston
 Allen Chauvenet
Ph: 304-388-1552
Wisconsin
  Green Bay
 St. Vincent Hospital Regional Cancer Center
 Clinical Trials Office - St. Vincent Hospital Regional Cancer Center
Ph: 920-433-8889
  Marshfield
 Marshfield Clinic - Marshfield Center
 Clinical Trials Office - Marshfield Clinic - Marshfield Center
Ph: 800-782-1581 ext. 94457
  Milwaukee
 Midwest Children's Cancer Center at Children's Hospital of Wisconsin
 Michael Kelly
Ph: 414-456-4170
Australia
South Australia
  North Adelaide
 Women's and Children's Hospital
 Maria Kirby
Ph: 61881617411
Western Australia
  Perth
 Princess Margaret Hospital for Children
 Catherine Cole
Ph: 011-6189340-8238
Canada
Alberta
  Calgary
 Alberta Children's Hospital
 Douglas Strother
Ph: 403-955-7272
  Edmonton
 University of Alberta Hospital
 Sunil Jayantilal` Desai
Ph: 780-407-8829
British Columbia
  Vancouver
 Children's & Women's Hospital of British Columbia
 Mason Bond
Ph: 604-875-2322
Manitoba
  Winnipeg
 CancerCare Manitoba
 Rochelle Yanofsky
Ph: 204-787-4163
Newfoundland and Labrador
  St. John's
 Janeway Children's Health and Rehabilitation Centre
 John (Jack) Hand
Ph: 709-777-4799
Nova Scotia
  Halifax
 IWK Health Centre
 Margaret Yhap
Ph: 902-470-8778
Ontario
  Kingston
 Cancer Centre of Southeastern Ontario at Kingston General Hospital
 Mariana Silva
Ph: 613-5496666x3833
  London
 Children's Hospital of Western Ontario
 A. Cairney
Ph: 519-685-8494
  Ottawa
 Children's Hospital of Eastern Ontario
 Jacqueline Halton
Ph: 613-737-7600x2370
  Toronto
 Hospital for Sick Children
 Sylvain Baruchel
Ph: 416-813-7795
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Mansoor Haq
Ph: 306-766-2498
  Saskatoon
 Saskatoon Cancer Centre at the University of Saskatchewan
 Kaiser Ali
Ph: 306-655-2744
New Zealand
  Auckland
 Starship Children's Health
 Lochie Teague
Ph: 64930749496368
Puerto Rico
  Santurce
 San Jorge Children's Hospital
 Luis Clavell
Ph: 787-728-1575
Switzerland
  Bern
 Swiss Pediatric Oncology Group Bern
 Roland Ammann
Ph: 41316329372

Related Information

PDQ® clinical trial COG-AREN03B2

Registry Information
Official Title Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Trial Start Date 2006-10-30
Trial Completion Date 2011-02-06 (estimated)
Registered in ClinicalTrials.gov NCT00352534
Date Submitted to PDQ 2006-05-23
Information Last Verified 2009-11-23
NCI Grant/Contract Number CA98543

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov